Clinical Trial

Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 9, 2024 (before its estimated April 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the effectiveness of Cadonilimab(AK104) in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
Trial Details
NCT Number NCT06406634
Lead Sponsor Hunan Cancer Hospital
Conditions Hepatocellular Carcinoma
Enrollment 30 participants
Start Date 2024-05-15
Primary Completion 2026-04-20 (estimated)
Study Completion 2027-04-20 (estimated)
Updated on ClinicalTrials.gov 2024-05-09